Revenue Growth and Gross Margin Expansion
For the full year 2024, Hyperfine reported $12.9 million in revenue, representing a 17% year-over-year increase. Gross profit for 2024 was $5.9 million, a 24% increase over 2023, with a full-year gross margin of 46%, up 300 basis points from 2023.
Cash Burn Reduction and Financial Strengthening
Hyperfine reduced its net cash burn by 9% in 2024, and completed a reorganization to lower operating costs, raising $6 million through a direct offering. The cash runway is extended to the end of 2026.
FDA Clearance and Software Releases
Two new AI-powered software releases are planned for 2025, expected to significantly improve image quality. The first technology update is anticipated by mid-2025, with the images comparable to conventional 1.5 Tesla MRI systems.
International and Office Market Expansion
In 2024, Hyperfine expanded its commercial focus internationally, securing 13 distributors across Europe, the Middle East, and Asia. Plans are in place to launch into neurology offices by mid-2025, enhancing market reach.